Envafolimab Combined With Endostatin in Recurrent or Metastatic MSS-type Colorectal Cancer
The objective is to investigate the efficacy and safety of envafolimab combined with recombinant human endostatin (endostatin) in the treatment of MSS-type colorectal cancer patients with recurrence or metastasis after failure of second-line standard therapy.
Colorectal Neoplasms
DRUG: Envafolimab|DRUG: recombinant human endostatin (endostatin)
ORR, Objective response rate, From Baseline to disease progress, up to 24 months
PFS, Progression Free Survival, From Baseline to primary completion date, about 2 years|OS, Overall Survival, From Baseline to primary completion date, about 2 years|DCR, Disease Control Rate, From Baseline to primary completion date, about 2 years|DOR, Duration of Response, From Baseline to primary completion date, about 2 years|SAE, severity Adverse Event, From Baseline to primary completion date, about 2 years
This study is a multicenter, prospective, single-arm clinical study. That is, eligible colorectal cancer patients, after signing the informed consent form, are screened into the group, and will receive continuous intravenous infusion of envafolimab (envafolimab) combined with recombinant human endostatin (endostatin) until the disease. Progressive or intolerable.